Streetbeat News

MED

Medifast, Inc.

Industry

Personal Products & Services

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Medifast has released its Q3 earnings guidance, projecting an EPS range of $(0.70)-$(0.05), which is below the estimated $(0.52). The company also expects revenue between $125M and $145M, significantly lower than the estimated $161.8M.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 8:38 pm

Medifast (NYSE:MED) reported Q2 2024 adjusted EPS of $0.92, significantly beating the analyst estimate of $0.39. However, sales of $168.558 million missed the $174.050 million estimate and were down 43.09% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 8:27 pm

DA Davidson analyst Linda Bolton Weiser maintains an Underperform rating on Medifast (NYSE:MED) with a $17.5 price target.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 8:16 pm

MEDIFAST shares are trading lower after DA Davidson downgraded the stock from Neutral to Underperform and lowered its price target from $25 to $17.5.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:02 pm

DA Davidson has downgraded Medifast (NYSE:MED) from Neutral to Underperform and lowered the price target from $25 to $17.5.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:00 pm

Medifast's (NYSE:MED) short interest has risen by 3.9%, with 45.02% of its float sold short. This is significantly higher than its peers' average of 5.01%. It would take traders 6.34 days to cover their short positions.

Portfolio Pulse from Benzinga Insights

May 31, 2024 | 3:30 pm

Medifast's (NYSE:MED) short interest has increased by 11.91% since the last report, with 2.99 million shares sold short, representing 41.53% of its float. This high level of short interest, compared to its peer group average of 4.98%, indicates a bearish market sentiment towards MED. However, an increase in short interest can sometimes be bullish, as covering short positions can drive the stock price up.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 2:30 pm

The article highlights the top 4 defensive stocks in the consumer staples sector that are currently oversold, presenting a potential buying opportunity. These include Medifast, Inc. (MED), Safety Shot, Inc. (SHOT), Molson Coors Beverage Company (TAP), and Australian Oilseeds Holdings Limited (COOT), all of which have an RSI near or below 30, indicating they may be undervalued.

Portfolio Pulse from Avi Kapoor

May 02, 2024 | 12:56 pm

H&E Equipment Services, Inc. (HEES) shares fell by 18.2% following mixed Q1 results, missing EPS estimates but beating sales expectations. Other stocks experienced significant movements, with notable gainers including Akili, Inc. (AKLI) and losers like Lichen China Limited (LICN). Various companies reported financial results, strategic partnerships, and other business updates affecting their stock prices.

Portfolio Pulse from Avi Kapoor

April 30, 2024 | 5:24 pm

DA Davidson analyst Linda Bolton Weiser maintains a Neutral rating on Medifast (NYSE:MED) and lowers the price target from $40 to $25.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 4:55 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.